BioCryst Participates in World Health Organization

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies

RESEARCH TRIANGLE PARK, N.C., Sept. 4, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced its participation in a consultation on potential Ebola therapies and vaccines hosted by the World Health Organization (WHO). The meeting is scheduled to take place September 4-5 in Geneva, Switzerland. According to the WHO, "The consultation has been convened to gather expertise about the most promising experimental therapies and vaccines and their role in containing the Ebola outbreak in west Africa." The meeting agenda and other information are available at:

http://www.who.int/mediacentre/events/meeting...ntions/en/

At the request of the WHO, BioCryst has furnished a one-page executive summary and a slide summary regarding BioCryst's broad spectrum antiviral BCX4430 as a drug candidate for the treatment of Ebola Virus Disease and other hemorrhagic fever virus diseases. These documents summarize: nonclinical disease model and safety research results; anticipated timelines for filing an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration to commence human safely studies of BCX4430; and projections for BCX4430 drug supply. 

Electronic versions of the executive summary and presentation provided to the WHO by BioCryst are available on the corporate website at www.biocryst.com .

About the BSAV Program & BCX4430

The objective of BioCryst's BSAV research program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to health and national security. The lead BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BioCryst is developing BCX4430 in collaboration with U.S. Government Agencies following the Animal Rule regulatory pathway.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including BCX4161 and several second generation compounds; peramivir , a viral neuraminidase inhibitor for the treatment of influenza, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com .

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that BioCryst or its licensees may not be able to enroll the required number of subjects in planned clinical trials of its product candidates and that such clinical trials, may not be successfully completed; that the Company or its licensees may not commence as expected additional pre-clinical studies or human clinical trials may not be commenced as expected or such studies may not be successfully completed; that the FDA may require additional studies beyond those planned for BCX4430, or may not provide regulatory clearances which may result in delay of planned clinical trials, or may impose a clinical hold BCX4430, or withhold market approval for product candidates; that the Company may not be able to obtain additional funding for BCX4430; that government funding or other contracts for BCX4430 may have certain terms and conditions, including termination provisions, that subject the Company to additional risks; that the Company may lose current funding for the program; that the Company may never file an IND for BCX4430; that its actual financial results may not be consistent with its expectations, including that 2014 operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.

BCRXW

Robert Bennett BioCryst Pharmaceuticals +1-919-859-7910

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 19

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 84

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 25

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 74

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 130

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 133

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 21

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Qfin Holdings Faces Securities Fraud Lawsuit Scrutiny

Updated Category News Views 23

Qfin Holdings Stumbles Under Legal Microscope Picture this—you're riding the stock market wave and then, out of nowhere, your investment gets hit by a sudden drop, leaving you scrambling for answers. That's the scenario investors in Qfin Holdings, Inc. (NASDAQ: QFIN) find themselves in after the company’s stock plunged by nearly 19%. Now, they're not just left...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 44

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights into Rathbones Group Plc's Position Disclosure

Updated Category News Views 171

Understanding Disclosure Requirements in Financial Markets In the world of finance and investments, transparency is paramount. Investors and market participants must be aware of regulations surrounding disclosure, especially when significant interest in relevant securities occurs. Here, we delve into key details surrounding a recent public disclosure by Rathbones Group...

Continue Reading
Atkore Inc. Announces Quarterly Cash Dividend for Shareholders

Updated Category News Views 139

Atkore Inc. Announces Cash Dividend for Shareholders Atkore Inc. (NYSE: ATKR), a prominent manufacturer known for its extensive electrical products, has informed its investors about the declaration of a quarterly cash dividend. This announcement signifies the company's ongoing commitment to providing value to its shareholders. The dividend is set at $0.32 per share of...

Continue Reading
Innovating Home Textiles: How CiCLO® is Changing Luxury Fabrics

Updated Category News Views 248

Innovative Technologies in Home Textiles An innovative fiber design blending renewable and biodegradable materials is advancing comfort, longevity, and responsible performance in premium home and hospitality textiles. At Heimtextil 2026, Intrinsic Advanced Materials will showcase a new generation of luxury textiles that embody sustainable practices, collaborating with...

Continue Reading
Vegan Food Industry Set for Huge Growth: USD 55.88 Billion by 2034

Updated Category News Views 271

Overview of the Vegan Food Market Growth The global vegan food market is anticipated to witness significant growth, increasing from USD 20.22 billion to an impressive USD 55.88 billion by 2034. This remarkable shift, with a compound annual growth rate (CAGR) of 10.7% from 2025 to 2034, reflects the rising consumer demand for plant-based options. Consumer Trends Driving...

Continue Reading
BAOS Stock Hits New Heights with Investor Enthusiasm

Updated Category News Views 190

BAOS Stock Surges to 52-Week High In a remarkable display of market confidence, Baosheng Media Group Holdings Limited (BAOS) has achieved a significant milestone by reaching a 52-week high of $7.33 per share. This surge demonstrates the strong backing from investors and the company's solid financial standing. Company Valuation and Financial Health The micro-cap company,...

Continue Reading